Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

With a market valuation of Rs 11,574.76 Cr, Sanofi Indias shares ended Fridays trading session on the BSE 0.58% higher at Rs ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Enveda, a Colorado-based biotech, has received a $20 million investment from French pharma major Sanofi. According to Enveda, ...

Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...